SCHEMBL52478

SCHEMBL52478

CCOC(=O)C=C(ON=C(N)C(NC(=O)OCc1ccccc1)[C@]1(C)CC[C@H](CO)C1(C)C)C(=O)OCC

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 15/20 0.37
TSHR P16473 9/20 0.37
ALDH1A1 P00352 8/20 0.37
SMN1; SMN2 Q16637 7/20 0.36
CASP1 P29466 1/20 0.36
CYP2C9 P11712 13/20 0.36
CYP2C19 P33261 12/20 0.36
CYP1A2 P05177 10/20 0.36
CYP2D6 P10635 9/20 0.36
LMNA P02545 4/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
MAPT P10636 1/20 0.35
MAPK1 P28482 2/20 0.35
CTSL P07711 2/20 0.35
HSD17B10 Q99714 1/20 0.35
LGMN Q99538 1/20 0.35
HTT P42858 1/20 0.33
CTSB P07858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL87197 0.78 CYP3A4 (0.42) CYP3A4TSHRALDH1A1SMN1; SMN2CASP1
SCHEMBL52055 0.71 CTSS (0.46) CYP3A4TSHRALDH1A1SMN1; SMN2CASP1
SCHEMBL62838 0.71 CYP3A4 (0.47) CYP3A4TSHRALDH1A1SMN1; SMN2CASP1
SCHEMBL52319 0.69 ITGB3 (0.33) CTSLLGMNCTSB
SCHEMBL51559 0.67 CTSS (0.38) TSHRALDH1A1CTSLCTSB
SCHEMBL13924823 0.66 NR1H4 (0.49) ALDH1A1LMNAMEN1KMT2AMAPT
SCHEMBL13657353 0.66 RORC (0.38) CYP3A4TSHRSMN1; SMN2CYP2C9CYP2C19
SCHEMBL87127 0.65 CYP3A4 (0.35) CYP3A4TSHRALDH1A1SMN1; SMN2CASP1
SCHEMBL51685 0.65 CYP3A4 (0.35) CYP3A4TSHRALDH1A1SMN1; SMN2CASP1
SCHEMBL62654 0.65 CTSS (0.35) TSHRCYP1A2CTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280981-B1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-04-23 EP disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG CYP3A4 319/4885TSHR 4845/4885ALDH1A1 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.